A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Sponsor: Boehringer Ingelheim
Listed as NCT05879978, this observational or N/A phase trial focuses on Neuroendocrine Neoplasms and Small Cell Lung Carcinoma (SCLC) and remains ongoing. Sponsored by Boehringer Ingelheim, it has been updated 24 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
24 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Feb 2026 — May 2026 [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
Phase: PHASE1/PHASE2 → PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 19 earlier versions
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
This study is open to adults with small cell lung cancer and other neuroendocrine tumours that are positive for the tumour marker Delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig that people can tolerate when taken together with another medicine called ezabenlimab. Obrixtamig and ezabenlimab may help the immune system fight cancer. Participants get obrixtamig and ezabenlimab as infusions into a vein. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about every week. The visits also depend on the response to the treatment. At the study visits, the doctors check the health of the participants, take necessary laboratory tests, and note any health problems that could have been caused by the study treatment.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .